Status:
UNKNOWN
Aortic Stenosis and Cardiac Amyloidosis
Lead Sponsor:
Medical University of Vienna
Collaborating Sponsors:
Allina Health System
Royal Free Hospital NHS Foundation Trust
Conditions:
Cardiac Amyloidosis
Aortic Stenosis
Eligibility:
All Genders
18+ years
Brief Summary
The dual pathology of aortic stenosis (AS) and cardiac amyloidosis (CA) is increasingly recognized. Even tough efforts have been undertaken to bring cohorts together, the largest cohort of AS-ATTR to ...
Detailed Description
Calcific aortic stenosis (AS) and transthyretin (ATTR) cardiac amyloidosis are both conditions commonly affecting the elderly. Bone scintigraphy using amyloid-avid tracers (99mTc-3,3-diphosphono-1,2-p...
Eligibility Criteria
Inclusion
- Patients with significant AS and a concomitant diagnosis of cardiac amyloidosis who are eligible for inclusion as per local permissions
Exclusion
- Patients without significant AS (less than moderate AS)
- Patients with other subtypes of cardiac amyloidosis (e.g., light chain)
Key Trial Info
Start Date :
March 1 2023
Trial Type :
OBSERVATIONAL
Allocation :
ESTIMATED
End Date :
December 31 2024
Estimated Enrollment :
300 Patients enrolled
Trial Details
Trial ID
NCT06129331
Start Date
March 1 2023
End Date
December 31 2024
Last Update
November 13 2023
Active Locations (2)
Enter a location and click search to find clinical trials sorted by distance.
1
Medical University of Vienna
Vienna, Austria, 1090
2
University College London
London, United Kingdom